Menu

Albireo to Present at Wedbush PacGrow Healthcare Conference

August 8, 2017

BOSTON — August 8, 2017 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid modulators, today announced that Ron
Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow
Healthcare Conference at Le Parker Méridien in New York City on Tuesday, August 15, 2017, at
4:15 ET.

A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s
website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is
recommended that users register at least 15 minutes prior to the scheduled start time. An archived
version of the webcast will be available for replay on the Events & Presentations section of the
Investors page of Albireo’s website for at least two weeks following the event.

For more information about the conference,
visit: https://www.wedbush.com/services/cmg/equities/corporate-access-events.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on
the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver
and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product
candidate, a Phase 2 product candidate, and a product candidate for which an application for
regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is
located in Gothenburg, Sweden. For more information on Albireo, please visit
http://www.albireopharma.com.

###
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com

Source: Albireo Pharma, Inc.

Albireo Homepage